Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Core Insights - Shattuck Labs has announced the discontinuation of its clinical program SL-172154 due to modest improvements in median overall survival in TP53 mutant acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) compared to azacitidine monotherapy benchmarks [1][6] - The company will shift its focus to SL-325, a first-in-class DR3 antagonist antibody intended for clinical development in inflammatory bowel disease (IBD), with an IND filing expected in Q3 2025 [1][8] - A restructuring plan is in place, which will reduce the workforce by approximately 40%, allowing the company to extend its cash runway into 2027 [1][11][10] Clinical Data Summary - For HR-MDS, the current median overall survival (OS) is 15.6 months, with TP53m HR-MDS patients showing a median OS of 10.6 months, which is not expected to improve beyond 13.1 months [4] - Benchmark data indicates a median OS of approximately 9–12 months for TP53m HR-MDS patients treated with azacitidine alone [4] - For TP53m AML, the current median OS is 10.5 months, with an expected maximum improvement to 11.7 months [5] - Benchmark data shows a median OS of approximately 5-8 months for TP53m AML patients treated with azacitidine alone [5] Corporate Developments - Shattuck has mutually agreed with Ono Pharmaceutical Co., Ltd. to terminate their collaboration and license agreement, relieving the company of any remaining performance obligations [7] - The company has implemented a restructuring plan to optimize its cost structure following the discontinuation of SL-172154, with a significant workforce reduction expected to be completed in Q4 2024 [10] - As of June 30, 2024, Shattuck reported cash and cash equivalents of $105.3 million, which is projected to fund operations into 2027 [9][11]